TABLE 4

Organ support, therapeutics, other interventions

Survivors (n=29)Nonsurvivors (n=14)Total (n=43)
Organ support
 Noradrenaline23 (79.3)14 (100)37 (86.0)
  Peak dose0.15 (0.09–0.32)0.23 (0.18–0.41)0.19 (0.11–0.35)
 Milrinone4 (13.8)5 (35.7)9 (20.9)
 Renal replacement therapy11 (37.9)8 (57.1)19 (44.2)
  Persisting requirement at step-down6 (20.7)
Immunomodulation25 (86.2)9 (64.3)34 (79.1)
 Methylprednisolone 1–2 mg·kg−124 (82.8)8 (57.1)32 (74.4)
 Anakinra7 (24.1)3 (21.4)10 (23.3)
 Methylprednisolone 1 g “pulsed”5 (17.2)4 (28.6)9 (20.9)
 Hydrocortisone1 (3.4)0 (0)0 (0)
Pharmacological intervention
 Remdesivir4 (13.8)0 (0)0 (0)
 Hydroxychloroquine2 (6.9)0 (0)0 (0)
ECMO circuit change11 (37.9)6 (42.9)17 (39.5)
 ECMO days per circuit change (mean)332930
Tracheostomy20* (69.0)5* (35.7)25 (58.1)
Post-decannulation lower limb DVT16 (55.2)1 (50.0) (n=2)17 (54.8) (n=31)
 Occlusive thrombus1 (6.3)0 (0)1 (3.2)
 Nonocclusive thrombus12 (75.0)1 (100)13 (41.9)
 Mural thrombus only3 (18.8)0 (0)3 (9.7)

Data are presented as n (%) or median (interquartile range), unless otherwise stated. DVT: deep vein thrombosis. *: p=0.01–0.05.